Garland Surgical (Cohort 8.0)

Accelerate Cohort 8.0 alumni Garland Surgical have announced the reception of €2.5 million in committed funds as part of €4 million seed round

We are extremely pleased to share some fantastic news from BetaDen Accelerate Cohort 8.0 founders Garland Surgical, who have secured €2.5 million in funding from NLC Health Ventures Health Impact Fund, Malta VC and a range of angel investors based in the United States and United Kingdom.

Garland Surgical - who are developing the innovative long-lasting hip replacement - the MaltaHip are continuing talks with additional investors to secure their full €4 million seed target ahead of the end of the round in September.

Simon Mifsud, Founder & CEO of Garland stated in a press release "We are grateful for the confidence our investors have shown in our vision and are excited to welcome additional partners as we complete the round."

We would like to offer a massive collective congratulations to Garland Surgical on achieving a hugely susbtantial funding milestone, as they continue their incredible progress on a vastly exciting and important project.

To read the full press release from Garland Surgical, use the link here.